Thyroid tumors are the most common endocrine malignancies. 1 The most common thyroid tumor (70%-80%) is the papillary thyroid carcinoma (PTC) which is the least aggressive form of TC because it has an indolent nature. 2 Follicular thyroid carcinoma (FTC), including Hürthle cell carcinoma, accounts for approximately 14% of thyroid cancers. It is more aggressive than papillary thyroid carcinoma, and may be associated with iodine deficiency. 2 Papillary and follicular carcinomas derive from follicular epithelial cells and are considered as differentiated thyroid cancers. Medullary thyroid carcinoma (MTC), which is a cancer of the C cells of the thyroid gland, accounts for 3% of thyroid cancers 2 , whereas anaplastic thyroid carcinoma (ATC/ Undifferentiated thyroid carcinoma) represents 2% of thyroid tumors and is the most aggressive form of thyroid cancer, which can metastasize early to the surrounding lymph nodes and distant sites.
Numerous studies have established VEGF-A as a key angiogenic factor in cancer. VEGF-A is expressed in various tumors and its expression associates with tumor progression. 3 Not only do tumor cells produce VEGF-A, but other cell types could also serve as a source of VEGF-A (hypoxic and ischemic conditions), such as stroma around the tumor. 4 VEGF-A is considered the main regulator of angiogenesis and therefore is a relevant factor in tumorigenesis of thyroid gland. [5] [6] [7] VEGF-A as a potent endothelial cell mitogen could serve as an important angiogenic stimulus in malignant tumors because it influences the proliferation, survival, migration and permeability of tumor cells. 8 The family of VEGF consists of seven members that include VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and placental growth factor (PlGF). 9 One of the most studied members of VEGF family is Folia Medica I 2019 I Vol. 61 I No. 1 VEGF-A. It has many functions, including its role in vascular permeability and stimulation of endothelial cell growth and angiogenesis. 10, 11 VEGF-A manifests its function after binding with its receptors (vascular endothelial growth factor receptors) which are tyrosine kinase receptors: VEGFR-1 and VEGFR-2, located mainly on endothelial cells. VEGFR-2 is responsible for signaling pathways, while VEGFR-1 has a regulatory role. 12 Initially, VEGF was considered an angiogenic factor with specific functions in endothelial cells. However, numerous studies have demonstrated that the role of VEGF is more complex, because it has an impact on the induction of tumor metastasis, inflammation, lymphangiogenesis, and even in neuroprotection and hepato-protection. 13, 14 There are conflicting reports concerning the role of VEGF in TC. According to some studies VEGF expression is not only higher in TC compared to normal thyroid tissue, but it can be used as a differentiating factor in TC metastases, invasion of lymph nodes and aggressiveness of the tumor and differentiating the transition of the tumors from low grade to high grade. [15] [16] [17] But not all authors agree with these findings. 18, 19 
AIM
The main focus of our study was to assess the VEGF-A expression in thyroid carcinomas and its association with different histopathological factors.
MATERIALS AND METHODS

Patients
This prospective study included a total of 80 patients. Of these 60 patients were histopathologically verified with TC after total thyroidectomy. 20 patients with benign thyroid tissue specimens served as a control group. Our selection included patients from the period between January 2000 and December 2015. Inclusion criteria were availability of tissue blocks, complete clinical data of the patients, and patients that had a total or near total thyroidectomy and no other known malignancy. The exclusion criteria were treatment with chemotherapy and monoclonal antibodies against VEGF receptors. Before surgery, all patients signed an informed consent form. This research was approved by the Ethics Committee of the Medical Faculty -University of Prishtina. The histopathological examinations of the 80 cases were performed at the Institute of Pathology, University Clinical Center of Kosovo.
Morphology
The prognosis and treatment of thyroid cancer depends on the tumor type and its stage at the time of diagnosis. 20 Histological types of thyroid cancer were defined according to the histological classification of WHO 2004. 20 Furthermore, prognostic features were evaluated by assessing the presence or absence of hemorrhage and necrosis.
Tumor staging
The tumor stage was determined from the post-total thyroidectomy specimens by using pTNM classification system/WHO 2004. 21 This classification system has been used to evaluate the tumor size, tumor invasion through the thyroid capsule (extrathyroidal spread), as well as involvement of the regional lymph nodes and regional and distant metastases.
Immunohistochemistry (IHC)
Eighty cases have been assessed immunohistochemically to evaluate the expression of VEGF-A in different histological types of thyroid cancer including papillary, follicular, medullary and anaplastic carcinoma, as well as in benign thyroid tissue, which was used as the control group. Thyroid tissues used for IHC evaluation were initially fixed by 10% buffered formalin phosphate. Then representative paraffin tumor blocks were selected after the evaluation of haematoxylin/eosin stained slides. These paraffin blocks were prepared using tumour tissues and from the periphery of the tumour adjacent to the normal tissues. After that, IHC was performed in 4 μm thick paraffin tissue sections. Slides were treated with standard procedures of rehydration in phosphate buffered saline (PBS). Endogenous peroxidase activity was inhibited by incubating the sections in 1% hydrogen peroxide, and then incubated in 2% goat serum in PBS to block nonspecific binding. The sections were then incubated for 30 min at room temperature with a rabbit anti-VEGF polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:200 dilution (0.5 μg/mL) using PBS and 1% BSA, and washed three times in PBS. The secondary antibody was goat antirabbit IgG (1:300 dilution; Vector Labs., Burlingame, CA). PBS replaced the primary antibody and was used as a negative control. VEGF-A protein expression was observed in the cytoplasm of the tumor cells. VEGF-A expression was quantified by evaluating the volume density and staining intensity on a three-grade scale. We used a semiquantitative scoring system, based on staining intensity (0 -negative; 1 -weak; 2 -intermediate; 3 -strong), which corresponded with the percentage of positive stained cells (0, 0%; 1, < 25% positive; 2, 26-50% positive; 3, ≥ 50% positive). VEGF-A expression was graded as negative or positive. The number of the patients according to staining intensity is given in Table 1 .
Statistical analysis
Chi-square test was used to evaluate differences in proportions of observations between independent groups. Fisher's test was used when the sample size 
RESULTS
The main characteristics of thyroid tumor types are presented in Table 2 . We analyzed three main characteristics in thyroid tumor types: age of the patients, sex of the patients and the expression of VEGF-A. There were 60 cases with different histological types of thyroid cancer, 23.3% men and 76.7% women with a median age of 55 years (range 18-89 years). Papillary carcinomas were more frequent in females (79.4%) than in males (20.6%). Also, follicular carcinomas were more frequent in females (82.4%) than in males (17.6%). Medullary carcinomas were presented in two females and in one male and anaplastic carcinomas were present in three females and in three males. Positive VEGF expression in all tumor cases tended to be more pronounced in females compared to males, but this did not reach statistical significance (p=0.098).
In thyroid carcinoma, VEGF-A was expressed in the cytoplasm of tumor cells, endothelial cells, and stromal fibroblasts (Fig. 1) .
The study showed that positive VEGF-A expression in all TC group was significantly higher than that in the benign thyroid tissues group (p<0.001). The comparison of the expression of VEGF-A showed that there was no significant difference between FTC and PTC (p=0.227). VEGF-A expression was detected in the cytoplasm of tumor cells in all thyroid tumor type. We analyzed VEGF-A expression and pathological characteristics of the tumor specimens according to the thyroid tumor type ( Table 3) . Our study did not show any association between the expression of VEGF-A and pathological characteristics of different histological types of thyroid tumors.
DISCUSSION
The process of angiogenesis is essential for the tumor growth and its progression. In this respect, VEGF-A is the most crucial factor that is responsible for tumor angiogenesis and vascular permeability. 22, 23 In our study, we evaluated the expression of VEGF-A in different histological types of TC. Our results showed that the VEGF-A expression in patients with TC was higher than that in benign thyroid tissue. These results are similar to earlier studies [15] [16] [17] that showed that thyroid tumors did express more VEGF than benign thyroid tissue. Furthermore, in the study done by Soh et al., higher expression of VEGF was confirmed by different methods, such as IHC (which was done both in cell lines and in paraffin-embedded tissues), northern blot and ELISA in different thyroid cell lines. 16 Additionally, Soh et al. measured the expression of VEGF messenger RNA (mRNA) in various thyroid cell lines.
The present study suggested that the presence of TC was significantly related to the sex of the patients; female patients were more dominant than male patients. This is no surprising considering the role of estrogens in the process of angiogenesis. 24 Furthermore, other studies have also confirmed female gender as a risk for TC. 25, 26 Statistics show that the incidence of thyroid cancer (0.5-10/ 100 000) increases with age, reaching a plateau after the age of 50. 24 In our study, median age of the patients with different histological types of TC was 55 years (range 18-89). These results are similar with the data from the study of Gulubova et al., where the median age of the patients was 55.6. 27 On the other hand, although our study found higher expression of VEGF-A in TC than in the control group, we did not find significant difference between VEGF-A expression values in TC and pathological characteristics of TC, such as tumor necrosis degree (p=0.565), angioinvasion (p=0.496), atypical mitosis (p=0.472), tumor size (p=0.950), metastasis (p=0.854) and lymphatic invasion (p=0.753). Similar results were reported by Huang et al. 28 In addition, Jukkola et al. 29 showed that immunohistochemical expression of VEGF-A did not associate with tumor size, but associated with the age of the patients and extracapsular invasion, although their data were based on scores from different staging classifications, like AGES system (patient age, tumor size, histological grade, tumor extent, distant metastases) and the MACIS system (metastasis, age, completeness of resection, invasion, tumor size). Although we had a lack of association between VEGF-A expression and the prognostic factors in TC, some studies have reported an association between higher VEGF-A immunostaining score and the presence of lymph node or distant metastases in papillary thyroid cancer. 30 According to these studies, other growth factors such as VEGF-C can impact tumor progression. We know that the family of VEGF is potent stimulators of endothelial cell growth, and while VEGF-A promotes hematological dissemination of the tumor, VEGF-C promotes lymphangiogenesis and facilitates the lymphatic dissemination. However, it is still not entirely known how differences in angiogenic or lymphangiogenic phenotype influence the route for tumor metastases.
In any case, combined use of VEGF-A and VEGF-C, and other angiogenic factors, could be used to improve the diagnostic accuracy and early detection of thyroid carcinoma, especially for the detection of aggressive forms of TC. 31 There are studies that suggest that there exists a significant association between tumor size and high levels of VEGF-A expression. 32 This study done by Bunone et al. also measured the expression of other angiogenic factors, such as VEGF-C, and angiopoietin-2 and their tyrosine kinase receptors KDR, Flt-4, and Tek. The role of these factors was analyzed in normal tissue, benign lesions, and different thyroid carcinomas. Authors of this study emphasized that the expression of one or more angiogenic factors in solid tumors such as TC is essential in promoting tumor growth. On the other hand, Soh et al. 16 found that medullary cancer produced less VEGF-A than the other thyroid cancer (that derive from follicular cells). This conclusion confirms the possibility that other angiogenic factors are more important in angiogenesis and invasion in medullary cancer. The complex role of different growth (including angiogenic) factors and their relationship are not completely understood, which should be an important subject for future investigations.
The important role of VEGF in tumor studies has resulted in new anti-tumor strategies, like the use of (anti -VEGF) antiangiogenic drugs for treatment in various tumors. There are different anticancer drugs which act on VEGF, VEGFR and VEGF signaling pathways. 33, 34 In TC, the first line of treatment is surgery and radioactive iodine therapy, but in cases when TC is resistant to radioactive iodine therapy, we should consider better treatment options. Tyrosine kinase inhibitors (sorafenib and lenvatinib) are used as drugs that inhibit the action of VEGF receptors. These two drugs were recently applied in the treatment of these tumors, where they have shown that they prolong progression free-survival, but not the overall survival. 35 In general, all the anti-VEGF drugs that were applied in recent clinical trials, have limited therapeutic success in TC, due to low response rate 36 and adverse effects in various tissues and organs 37 . That is why it is necessary to conduct more investigations, which should be focused on molecular studies that could result in a novel antiangiogenesis therapy as an effective treatment for thyroid tumors. 38 
CONCLUSIONS
In conclusion, finding an appropriate biochemical marker for thyroid carcinomas remains a challenge. There are few new markers that have a real diagnostic or prognostic value. Based on our study, VEGF-A expression is upregulated in thyroid cancers compared with benign tissue and it would be useful to perform IHC staining for VEGF-A expression as a valuable diagnostic factor in differentiating TC from benign thyroid tissue.
